Talking Points

Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.

How has the pharmacotherapy for STEMI changed over the past 46 years? Ginger Jiang and C. Michael Gibson discuss treating patients with zalunfiban at first medical contact.

Colin Berry and C. Michael Gibson discuss whether stress CMR imaging is helpful in patients with angina and no obstructive CAD.

Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and multivessel CAD undergoing PCI.

C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.

Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.

Thomas Crawford meets with C. Michael Gibson to discuss the role of reconditioned pacemakers in low- and middle-income countries.

C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.

Mamas Mamas, Birgitte Krogsgaard Andersen, and Niels Ramsing Holm discuss QFR versus FFR for guiding resvascularization in patients with coronary stenoses.

James Benenati, Robert Lookstein, and Rachel Rosovsky discuss the STORM-PE trial, the first-of-its-kind RCT for acute intermediate-high risk pulmonary embolism (PE).

For patients with aortic stenosis, is earlier intervention beneficial? Mamas Mamas, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss.

TCTMD_Talking Points_BTD EPIC-CAD Trial by TCTMD

Ajay Kirtane and C. Michael Gibson discuss how orbital atherectomy compares with balloon angioplasty for severely calcified coronary arteries before DES implantation.

Does long-term colchicine benefit patients after acute MI? C. Michael Gibson and Sanjit Jolly discuss.

Mamas Mamas talks to Jacob Thomsen Lønborg about how revascularization with PCI affects outcomes for patients with stable CAD undergoing TAVI.

Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current barriers faced by referring specialists.

Johanne Silvain, Gilles Montalescot, and C. Michael Gibson discuss the effects of beta-blocker interruption in post-MI patients.

Patient selection is important for transcatheter interventions and impacts result success. This discussion focuses on defining what treatment goals should be, limitations of current interventions, and identifying appropriate transcatheter patients.

Paul Ridker and C. Michael Gibson discuss 30-year data hinting at how three modifiable factors—LDL, hs-CRP, and lp(a)—might be leveraged to reduce long-term risk.

Clinical trials face challenges with variability in echo images, protocol adherence, and data quality. This discussion focuses on strategies to improve trial integrity, operational efficiency, and regulatory approval of transcatheter devices.